Aradigm Corporation (NASDAQ:ARDM) Files An 8-K Other Events

Aradigm Corporation (NASDAQ:ARDM) Files An 8-K Other Events
Item 8.01 – Other Events.

Story continues below

On July7, 2017, the Principal Investigator, Charles Haworth, MD, FRCP, for the Phase 3 ORBIT-3 and ORBIT-4 clinical trials (the “Studies”) of Aradigm Corporation (the “Company”) presented the analysis of the results for such trials, which investigated the safety and efficacy of the Company’s investigational drug product Linhaliq™, at the 2nd World Bronchiectasis Conference in Milan, Italy. Additionally, Igor Gonda, PhD, President and Chief Executive Officer of Aradigm, presented two posters on the Studies; the first poster presented additional microbiological results and the second presented pharmacokinetics results. All three presentations will be available on the Company’s website as soon as possible following the conference. The presentation abstracts are attached as Exhibit 99.1 to this Current Report on Form 8-K and are incorporated herein by reference.

Item 8.01 – Financial Statements and Exhibits

(d) Exhibits



99.1 Presentation abstracts on Phase 3 ORBIT-3 and ORBIT-4 clinical trials of Aradigm Corporation

EX-99.1 2 d403553dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Inhaled Liposomal Ciprofloxacin In Patients With Bronchiectasis And Chronic Pseudomonas Aeruginosa Infection: Results From Two Parallel Phase III Trials (ORBIT-3 and ORBIT-4) C. Haworth1,…
To view the full exhibit click here

About Aradigm Corporation (NASDAQ:ARDM)

Aradigm Corporation is a pharmaceutical company focused on the development and commercialization of products for the treatment and prevention of severe respiratory diseases. The Company’s lead product candidate is Pulmaquin inhaled ciprofloxacin, which is in Phase III clinical trials. It offers AERx pulmonary drug delivery platform and other technologies. Its partnered programs under development include Inhaled Ciprofloxacin. It is also engaged in developing Smoking Cessation Therapy (ARD-1600 Inhaled Nicotine). Its lead development candidates are its formulations of the potent antibiotic ciprofloxacin (Pulmaquin (ARD-3150) and Lipoquin (ARD-3100)) that are delivered by inhalation for the management of infections associated with the severe respiratory diseases, such as cystic fibrosis (CF) and non-cystic fibrosis bronchiectasis (BE). Pulmaquin uses slow release liposomal formulation (Lipoquin) mixed with a small amount of ciprofloxacin dissolved in an aqueous medium.

An ad to help with our costs